BridgeBio Pharma, Inc. (BBIO) · Oct 13, 2026 · Other events
Priority Review granted — PDUFA target action date: February 4, 2027
BridgeBio’s infigratinib NDA won FDA Priority Review, setting a February 4, 2027 action date after compelling achondroplasia data.
BridgeBio is moving from positive late-stage data toward a potential first achondroplasia launch: PROPEL 3 has already delivered the pivotal efficacy readout, and infigratinib is now in formal FDA review. The company’s broader pipeline is also shifting into regulatory execution, making this a development-to-commercial transition rather than a new clinical proof point.
The regulatory path is now faster and more concrete. The FDA accepted the NDA and granted Priority Review, with a February 4, 2027 PDUFA target date. 〔0〕 That advances the story from “strong Phase 3 program awaiting submission” to “a reviewable product with a defined approval decision,” although Priority Review is not an approval and the filing still leaves regulatory uncertainty intact.
The clinical case is strong, but mostly not new today. PROPEL 3’s primary endpoint, height Z-score secondary endpoint, and statistically significant body-proportionality result were previously disclosed; the filing mainly packages those results alongside the regulatory milestone. 〔1〕 The reported +2.10 cm/year AHV treatment effect and significant proportionality and arm-span results strengthen the approval narrative, but they are confirmation rather than a fresh surprise.
The broader medical-outcome narrative is supportive but still exploratory. Favorable trends in sleep apnea and otitis media could widen the product’s value beyond height, but these are not the same as confirmed pivotal efficacy outcomes. 〔2〕
Bottom line: This is a meaningful regulatory de-risking step for an already validated clinical story, not a new efficacy breakthrough. The key next value-bearing event is the FDA decision on February 4, 2027, when BridgeBio’s Phase 3 profile faces the approval test.
FDA action on February 4, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!